eQcell Inc.

📍 Guelph, Canada🗓 Founded 2010👥 14 employees💰 Last funded Jul 2024
Biotechnology Research🌐 eqcell.com
Website LinkedIn
eQcell™ Inc. is Canada’s premier clinical-stage regenerative medicine company. Founded by Dr. Thomas Koch, Assistant Professor at Canadas University of Guelph, his work reflects 15 years of stem cell research and some $6 million of research investment. The companys target is regenerative therapies for human health utilizing the pathway of conditions and diseases affecting sporting and companion animals globally for which current treatments are ineffective, not fully effective, or palliative. eQcell has developed allogeneic equine cord blood stem cells, for which Dr. Koch published the worlds first paper, and is producing canine adipose-derived mesenchymal stromal cells to provide novel therapeutic options. eQcell’s initial concentration in veterinary therapy is designed to most rapidly achieve marketing approval for its veterinary regenerative stem cells, in the process generating data leading to a scientifically and economically-effective pathway for translation into similar human applications. eQcell is a leader in the now-established science bridging development of therapeutics for both humans and animal health.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2010
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in eQcell Inc.?
eQcell Inc. has 1 investors on record on gritt.io.
When did eQcell Inc. last raise funding?
The most recent investment in eQcell Inc. recorded on gritt.io was in July 2024.
When was eQcell Inc. founded?
eQcell Inc. was founded in 2010.
What industry is eQcell Inc. in?
eQcell Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is eQcell Inc. based?
eQcell Inc. is headquartered in Guelph, Canada.